We know that obesity is a complex disease that affects people in different ways and increases the risk of many other serious, related conditions. By listening to the experiences of people who are living with weight-related conditions, as well as healthcare professionals around the world, we continue to deepen our understanding of these diseases.
Our researchers have developed an investigational medicine (a monthly injection) called maridebart cafraglutide (MariTide). The MARITIME Phase 3 clinical studies are exploring how safe and effective MariTide is in reducing body weight and addressing obesity related diseases.
We are currently studying or plan to study:
MARITIME-1
Overweight or obesity
Active, not recruiting
MARITIME-2
Type 2 diabetes
Active, not recruiting
MARITIME-CV
Cardiovascular disease (also called heart disease)
Recruiting
MARITIME-HF
Heart failure
Recruiting
MARITIME-OSA
Obstructive sleep apnea
Recruiting
Additional studies may be announced in the future.